Research Triangle Park, North Carolina -- Pulmonary treatment developer BioMarck Pharmaceuticals has raised $7 million in new equity venture capital funding, according to an SEC regulatory filing.
BioMarck is developing a portfolio of products "utilizing MARCKS technology for the treatment of cancer and acute respiratory distress syndrome (ARDS)."
The company is currently focused on its lead compound, BIO-11006 for non-small cell lung cancer and acute respiratory distress syndrome, for which it has active INDs for both indications.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of seven investors participated in the financing.